Literature DB >> 2782976

Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.

V Kyle1, B L Hazleman.   

Abstract

In a prospective study of 74 patients and a retrospective study of 35 patients with polymyalgia rheumatica/giant cell arteritis steroid related side effects occurred in at least one third of patients, and in two thirds if weight gain was included. Side effects were significantly related to an initial prednisolone dose of more than 30 mg and to the cumulative prednisolone dose. Patients taking a mean daily dose of 5 mg prednisolone or less were significantly less likely to develop side effects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2782976      PMCID: PMC1003843          DOI: 10.1136/ard.48.8.662

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

1.  Long-term follow-up of polymyalgia rheumatica.

Authors:  H Spiera; S Davison
Journal:  Mt Sinai J Med       Date:  1978 Mar-Apr

2.  Treatment and prognosis in polymyalgia rheumatica and temporal arteritis. A ten-year survey of 53 patients.

Authors:  J von Knorring
Journal:  Acta Med Scand       Date:  1979

3.  Temporal arteritis, steroid therapy, and pulmonary emboli.

Authors:  S A Uriu; R D Reinecke
Journal:  Arch Ophthalmol       Date:  1973-11

4.  HLA antigens and corticosteroid response.

Authors:  B Becker; D H Shin; P F Palmberg; S R Waltman
Journal:  Science       Date:  1976-12-24       Impact factor: 47.728

5.  Polymyalgia rheumatica and giant cell arteritis: a seven-year survey.

Authors:  A B Myles
Journal:  Rheumatol Rehabil       Date:  1975-11

6.  Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids.

Authors:  B A Bengtsson; B E Malmvall
Journal:  Acta Med Scand       Date:  1981

7.  Temporal arteritis in Israel. A review of 47 patients.

Authors:  M Fainaru; G Friedman; B Friedman
Journal:  J Rheumatol       Date:  1979 May-Jun       Impact factor: 4.666

8.  Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study.

Authors:  K A Huston; G G Hunder; J T Lie; R H Kennedy; L R Elveback
Journal:  Ann Intern Med       Date:  1978-02       Impact factor: 25.391

9.  Prognosis and management of polymyalgia rheumatica.

Authors:  J G Jones; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1981-02       Impact factor: 19.103

10.  Prognosis in giant-cell arteritis.

Authors:  E Graham; A Holland; A Avery; R W Russell
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-24
View more
  29 in total

1.  Clinical guidelines: Unraveling the tautology of polymyalgia rheumatica.

Authors:  Eric L Matteson
Journal:  Nat Rev Rheumatol       Date:  2010-05       Impact factor: 20.543

Review 2.  Stopping steroids in polymyalgia rheumatica and giant cell arteritis.

Authors:  V Kyle; B L Hazelman
Journal:  BMJ       Date:  1990-02-10

3.  Giant cell arteritis.

Authors:  J C Mason; M J Walport
Journal:  BMJ       Date:  1992-07-11

Review 4.  Polymyalgia rheumatica.

Authors:  Clement J Michet; Eric L Matteson
Journal:  BMJ       Date:  2008-04-05

5.  Polymyalgia rheumatica and giant cell arteritis. High dose corticosteroids are recommended.

Authors:  J Ferris; R Lamb
Journal:  BMJ       Date:  1995-08-12

Review 6.  Updates in the Diagnosis and Management of Giant Cell Arteritis.

Authors:  Surabhi Uppal; Mohanad Hadi; Sheetal Chhaya
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-08       Impact factor: 5.081

Review 7.  Clinical diagnosis and management of large vessel vasculitis: giant cell arteritis.

Authors:  Soumya Chatterjee; Scott D Flamm; Carmela D Tan; E Rene Rodriguez
Journal:  Curr Cardiol Rep       Date:  2014-07       Impact factor: 2.931

8.  Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

9.  The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica.

Authors:  S Schreiber; M Buyse
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

10.  Characteristics of adverse effects when using high dose short term steroid regimen.

Authors:  Kyung Hyun Min; Chung-Ku Rhee; Jae Yun Jung; Myung-Whan Suh
Journal:  Korean J Audiol       Date:  2012-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.